Nasdaq · Biotech stocks database
OTLK (Outlook Therapeutics Inc.) stock: $0.44, $106.2M market cap, $11.2M cash, $95.0M EV, $127.6M fully diluted market cap. Next expected readout: Dec-27. Lead program: bevacizumab (Age-Related Macular Degeneration), Phase 3. Data from Fully Diluted's biotech stocks database.
We are a biopharmaceutical company that has developed ONS-5010/LYTENAVA TM as the first ophthalmic formulation of bevacizumab approved by the European Commission in the European Union, or EU, and the Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom, or UK, for use in adults for the treatment of wet age-related macular degeneration, or wet AMD.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $11.2M |
|---|---|
| Debt | $0.0M |
| Net cash | $11.2M |
| Enterprise value | $95.0M |
| Basic shares | 243.4M shares |
| Fully diluted shares | 290.0M shares |
| Fully diluted market cap | $127.6M |
| Cash per share | $0.05 |
| Quarterly burn | $21.0M |
| Cash runway | 0.5 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading OTLK daily closes…
bevacizumab · Jan 12 - Feb 23 in 14 mo · Phase 3 · Age-Related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration